The SFKi dasatinib and eCF506 significantly attenuated tumor growth, downregulated FOXM1 expression, and induced gene expression changes consistent with FOXM1 inhibition in the luminal-like PDX (Figure 10C and Supplemental Figure 11B). The gene discussed is FOXM1; the disease is neoplasm.